Malignant Pleural Mesothelioma (MM) is an asbestos-related malignancy which is detected at an advanced stage when curative options are not feasible. Sensitive and specific biomarkers which predict that an asbestos-exposed, high-risk-for-MM individual will develop MM do not exist. By combining the efforts of investigators in the United States and Australia at centers which are known for their expertise in bench work investigations and novel protocols for MM, a multifaceted approach for the rapid discovery and eventual validation of markers of early mesothelial carcinogenesis will be undertaken. This consortium will have the largest collection of reagents for biomarker discovery in MPM in the world, both as archived and prospectively collected specimens. The centers will be linked initially through the refinement of the potential mesothelial biomarker SMRP (soluble members of the mesothelin/Megakaryocyte Potentiating Factor related protein) building on already established industrial collaborations. Preliminary data reveals selective upregulation in sera and pleural effusions of MPM patients compared to other cancers and asbestos exposed individuals. Standards for the normal range of SMRP in asbestos exposed individuals will be established using an already existing >2000 patient Australian serum archive, and the positive/negative predictive value of the ELISA will be determined using existing and prospectively collected sera from MM patients. Both the US and Australian sites will also use the Affymetrix Expression Array Platform to define new soluble biomarkers by comparing non-cancerous mesothelium to early stage, resected mesothelioma tumors from the investigators archives. Preliminary data combining gene expression data with pathway analyses for secreted proteins suggests that osteopontin, MMP-3, and Cartilage Link Protein 1 could be promising markers for the detection of MPM. Further validation of these markers as well as the development of reagents for promising novel biomarkers will be performed at both the US and the Australian sites. ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (M2))
Program Officer
Krueger, Karl E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
Birse, Charles E; Tomic, Jennifer L; Pass, Harvey I et al. (2017) Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules. Clin Proteomics 14:25
Bononi, Angela; Yang, Haining; Giorgi, Carlotta et al. (2017) Germline BAP1 mutations induce a Warburg effect. Cell Death Differ 24:1694-1704
Romero, Rodrigo; Sayin, Volkan I; Davidson, Shawn M et al. (2017) Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med 23:1362-1368
Napolitano, Andrea; Antoine, Daniel J; Pellegrini, Laura et al. (2016) HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res 22:3087-96
Pass, Harvey I; Goparaju, Chandra; Espin-Garcia, Osvaldo et al. (2016) Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. J Thorac Oncol 11:900-9
Fahrmann, Johannes F; Grapov, Dmitry; Phinney, Brett S et al. (2016) Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival. Clin Proteomics 13:31
Lee, L James; Yang, Zhaogang; Rahman, Mohammad et al. (2016) Extracellular mRNA Detected by Tethered Lipoplex Nanoparticle Biochip for Lung Adenocarcinoma Detection. Am J Respir Crit Care Med 193:1431-3
Carbone, Michele; Kanodia, Shreya; Chao, Ann et al. (2016) Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 11:1246-1262
Wang, Jie; Shivakumar, Shilpa; Barker, Kristi et al. (2016) Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules. J Thorac Oncol 11:334-45
Vachani, Anil; Pass, Harvey I; Rom, William N et al. (2015) Validation of a multiprotein plasma classifier to identify benign lung nodules. J Thorac Oncol 10:629-37

Showing the most recent 10 out of 26 publications